Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.

ABSTRACT:

Purpose

To assess changes in retinal nonperfusion (RNP) in patients with retinal vein occlusion (RVO) treated with ranibizumab.

Design

Secondary outcome measure in randomized double-masked controlled clinical trial.

Participants

Thirty-nine patients with central RVO (CRVO) and 42 with branch RVO (BRVO).

Methods

Subjects were randomized to 0.5 or 2.0 mg ranibizumab every month for 6 months and then were re-randomized to pro re nata (PRN) groups receiving either ranibizumab plus scatter laser photocoagulation or ranibizumab alone for an additional 30 months.

Main outcome measures

Comparison of percentage of patients with increased or decreased area of RNP in patients with RVO treated with 0.5 versus 2.0 mg ranibizumab, during monthly injections versus rani

SUBMITTER: Mir TA 

PROVIDER: S-EPMC5482175 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature